Safety and Effectiveness of TaurusTrio™ Heart Valve System in Patients With Severe Aortic Regurgitation (AR)
A trial with no phase registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 116 participants.
Also called NCT06101888
- Study
- In this atlas
Overview
- Design
- Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase
- Not applicable
- Enrolled
- 116 participants
- Registry
-
NCT06101888
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- China
- Registry status
- Recruiting
Technical summary
Registry record NCT06101888. Allocation not applicable; no masking; primary purpose treatment. Start 2023-08-01 (actual); primary completion 2024-07-31 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Safety and Effectiveness of TaurusTrio™ Heart Valve System in Patients With Severe Aortic Regurgitation (AR)
- Condition
- Aortic Regurgitation
- Intervention (Device)
- TaurusTrio™ Heart Valve System
- Lead sponsor
- Peijia Medical Technology (Suzhou) Co., Ltd.
Record details
- Record id
cardio:ct-nct06101888- Content hash
a6421a5254b81bcaf103630094950c1fa65594091b4ddd0bd8a634d49a05e80f